Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07589517 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer

Name: Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer — clinical trial record (NCT07589517)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DUO-CRC-NK-111

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-02-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

Colorectal Cancer

2,904 trials monitored

See 127 trials at risk

This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic colorectal cancer (CRC). Participants are assigned to one of three dual-target arms based on tumor antigen co-expression: (1) CEA+GUCY2C, (2) CEA+HER2, or (3) GUCY2C+HER2. Following dose escalation, the most suitable target pair (based on safety, feasibility, and early efficacy/biomarker signals) will be selected for dose expansion.

Trial Details

NCT Number	NCT07589517
Lead Sponsor	Beijing Biotech
Conditions	Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
Enrollment	48 participants
Start Date	2026-02-02
Primary Completion	2027-03-14 (estimated)
Study Completion	2028-03-17 (estimated)
Updated on ClinicalTrials.gov	2026-05-15